TechImmune

TechImmune is a clinical-stage biotechnology company focused on developing next-generation vaccines that elicit broad and durable T-cell immunity. The company's proprietary platform identifies highly conserved epitopes across virus variants to create vaccines that remain effective even as pathogens mutate. Its lead candidate, TI-1001, is a COVID-19 vaccine designed to provide protection against multiple variants by targeting internal viral proteins in addition to the spike protein. TechImmune aims to address the limitations of current antibody-focused vaccines by providing long-lasting cellular protection. The company is also expanding its pipeline to include universal vaccines for other infectious diseases, such as influenza. Headquartered in Newport Beach, California, TechImmune leverages expertise in immunology and clinical trial design to advance its mission of global pandemic preparedness.